Surrozen, Inc. (SRZN)
SRZN Stock Price Chart
Explore Surrozen, Inc. interactive price chart. Choose custom timeframes to analyze SRZN price movements and trends.
SRZN Company Profile
Discover essential business fundamentals and corporate details for Surrozen, Inc. (SRZN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Jan 2021
Employees
42.00
Website
https://www.surrozen.comCEO
Craig Parker
Description
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
SRZN Financial Timeline
Browse a chronological timeline of Surrozen, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 14 Aug 2026
EPS estimate is -$1.29, while revenue estimate is $467.25k.
Earnings released on 6 May 2026
EPS came in at -$11.65 falling short of the estimated -$1.39 by -738.13%, while revenue for the quarter reached $5.00m , beating expectations by +25.00%.
Earnings released on 23 Mar 2026
EPS came in at -$7.59 falling short of the estimated -$1.41 by -438.30%, while revenue for the quarter reached $514.00k , missing expectations by -22.24%.
Earnings released on 7 Nov 2025
EPS came in at -$3.61 falling short of the estimated -$1.17 by -208.55%, while revenue for the quarter reached $983.00k .
Earnings released on 8 Aug 2025
EPS came in at -$1.14 surpassing the estimated -$1.23 by +7.32%, while revenue for the quarter reached $983.00k .
Earnings released on 9 May 2025
EPS came in at -$3.13 falling short of the estimated -$1.09 by -187.16%, while revenue for the quarter reached $983.00k .
Earnings released on 31 Mar 2025
EPS came in at -$9.10 falling short of the estimated -$2.54 by -258.27%, while revenue for the quarter reached $655.00k .
Earnings released on 6 Nov 2024
EPS came in at -$0.44 surpassing the estimated -$2.77 by +84.12%, while revenue for the quarter reached $10.00m .
Earnings released on 12 Aug 2024
EPS came in at -$1.54 surpassing the estimated -$2.79 by +44.80%.
Earnings released on 8 May 2024
EPS came in at -$4.24 surpassing the estimated -$4.25 by +0.24%.
Earnings released on 27 Mar 2024
EPS came in at -$4.41 falling short of the estimated -$3.00 by -47.00%, while revenue for the quarter reached $4.15m .
Stock split effective on 14 Dec 2023
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 Nov 2023
EPS came in at -$4.35 falling short of the estimated -$4.20 by -3.57%.
Earnings released on 9 Aug 2023
EPS came in at -$4.65 surpassing the estimated -$6.00 by +22.50%.
Earnings released on 10 May 2023
EPS came in at -$7.20 falling short of the estimated -$5.10 by -41.18%.
Earnings released on 22 Mar 2023
EPS came in at -$0.45 surpassing the estimated -$6.75 by +93.33%, while revenue for the quarter reached $12.50m .
Earnings released on 14 Nov 2022
EPS came in at -$5.70 surpassing the estimated -$6.45 by +11.63%.
Earnings released on 11 Aug 2022
EPS came in at -$6.00 surpassing the estimated -$6.90 by +13.04%.
Earnings released on 11 May 2022
EPS came in at -$3.45 surpassing the estimated -$8.10 by +57.41%.
Earnings released on 24 Mar 2022
EPS came in at -$5.25 surpassing the estimated -$7.80 by +32.69%.
Earnings released on 15 Nov 2021
EPS came in at -$0.51 falling short of the estimated -$0.38 by -34.21%.
Earnings released on 6 Aug 2021
EPS came in at -$0.36 .
SRZN Stock Performance
Access detailed SRZN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
